Abstract: Provided herein are proteins comprising a novel antigen binding domain. Said antigen binding domain, and proteins comprising it, are able to bind to osteosarcoma cells under physiological conditions. The antigen binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH), each comprising three complementarity determining regions (CDRs) flanked by human framework sequences. The human framework sequences reduces the risk of triggering unwanted immunogenic responses against the antigen binding domain. This may be especially important in a therapeutic setting wherein a drug is administered repeatedly to a human osteosarcoma patient.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTNI), or block blood monocytes that abnormally express ASTNI from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTNI for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTN1), or block blood monocytes that abnormally express ASTN1 from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTN1 for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTN1), or block blood monocytes that abnormally express ASTN1 from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTN1 for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: This disclosure relates in general to the field of antibody modeling and analysis. The disclosed subject matter describes a single online workspace to model and analyze antibody sequences or structures. Modeling and analysis may be performed by employing a number of features including, but not limited to, sequence analysis, structure analysis, antibody modeling, packing, antibody humanization, mutations, design, loop modeling, protein-protein docking, and scoring.